Abstract
Aim:
The present study was designed to investigate the expression of Polo-like kinase 1 (PLK1) and survivin in non-Hodgkinos lymphoma (NHL).
Methods:
The expression of PLK1 and survivin were detected with immunohistochemical techniques.
Results:
The expression rate of PLK1 and survivin were 63.6% (56/88) and 79.5% (70/88) in NHL, respectively. PLK1 expression correlated with systemic symptoms, lactate dehydrogenase levels, and international prognostic index scores in B-NHL and T-NHL, while survivin did not.
Conclusion:
PLK1 and survivin are both overexpressed in NHL. There is a significant relationship between the overexpression of PLK1 and clinical features.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cell Cycle Proteins / genetics
-
Cell Cycle Proteins / metabolism*
-
Child
-
Child, Preschool
-
Cyclophosphamide / therapeutic use
-
Doxorubicin / therapeutic use
-
Humans
-
Immunohistochemistry
-
Inhibitor of Apoptosis Proteins
-
Lymphoma, Non-Hodgkin / drug therapy*
-
Lymphoma, Non-Hodgkin / genetics
-
Lymphoma, Non-Hodgkin / pathology*
-
Microtubule-Associated Proteins / genetics
-
Microtubule-Associated Proteins / metabolism*
-
Middle Aged
-
Neoplasm Staging
-
Polo-Like Kinase 1
-
Prednisone / therapeutic use
-
Protein Serine-Threonine Kinases / genetics
-
Protein Serine-Threonine Kinases / metabolism*
-
Proto-Oncogene Proteins / genetics
-
Proto-Oncogene Proteins / metabolism*
-
Survivin
-
Treatment Outcome
-
Vincristine / therapeutic use
-
Young Adult
Substances
-
BIRC5 protein, human
-
Cell Cycle Proteins
-
Inhibitor of Apoptosis Proteins
-
Microtubule-Associated Proteins
-
Proto-Oncogene Proteins
-
Survivin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Protein Serine-Threonine Kinases
-
Prednisone